Trials
Search / Trial NCT00002471

Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Aug 27, 2004

Apply for Trial

Trial Information

Current as of March 16, 2025

Completed

Keywords

Childhood Burkitt Lymphoma L3 Childhood Acute Lymphoblastic Leukemia B Cell Childhood Acute Lymphoblastic Leukemia L3 Adult Acute Lymphoblastic Leukemia B Cell Adult Acute Lymphoblastic Leukemia Recurrent Adult Non Hodgkin Lymphoma Stage Iii Adult Diffuse Large Cell Lymphoma Stage Iii Adult Immunoblastic Large Cell Lymphoma Stage Iii Adult Burkitt Lymphoma Stage Iv Grade 3 Follicular Lymphoma Stage Iv Adult Diffuse Large Cell Lymphoma Stage Iv Adult Immunoblastic Large Cell Lymphoma Stage Iv Adult Burkitt Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Burkitt Lymphoma Stage Iii Childhood Small Noncleaved Cell Lymphoma Stage Iv Childhood Small Noncleaved Cell Lymphoma Stage Iv Childhood Large Cell Lymphoma Recurrent Childhood Small Noncleaved Cell Lymphoma Recurrent Childhood Large Cell Lymphoma

ClinConnect Summary

OBJECTIVES: I. Improve the survival of children and adolescents with poor-risk nonlymphoblastic lymphoma and acute B-lymphoblastic leukemia using an intensive, short-course regimen of combination chemotherapy. II. Assess the toxicity of the regimen.

OUTLINE: Nonrandomized study. Induction: 7-Drug Combination Chemotherapy with Leucovorin Rescue plus Triple Intrathecal Therapy (TIT). Cyclophosphamide, CTX, NSC-26271; Thiotepa, TSPA, NSC-6396; Vincristine, VCR, NSC-67574; Daunorubicin, DNR, NSC-82151; Dexamethasone, DM, NSC-34521; Etoposide, VP-16, NSC-141540; Methotrexate, MTX, NSC-740; with...

Gender

ALL

Eligibility criteria

  • • DISEASE CHARACTERISTICS: Newly diagnosed undifferentiated nonlymphoblastic non-Hodgkin's lymphoma (Burkitt's or non-Burkitt's) Newly diagnosed large cell lymphoma with CNS involvement Recurrent non-Hodgkin's lymphoma L-3 and B-cell leukemia included At least 1 of the following required: LDH at least 500 IU/liter (old method) or 2,000 IU/liter (new method) Bone marrow involvement (greater than 5% lymphoblasts) CNS involvement (lymphoblasts on CSF cytospin or intracranial mass on CT or MRI scan)
  • • PATIENT CHARACTERISTICS: Age: Any age Performance status: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified
  • • PRIOR CONCURRENT THERAPY: Prior therapy allowed for non-Hodgkin's lymphoma No prior therapy for all other diseases

Trial Officials

Norma Wollner, MD

Study Chair

Memorial Sloan Kettering Cancer Center

About Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSKCC) is a world-renowned institution dedicated to cancer treatment, research, and education. As a leading clinical trial sponsor, MSKCC focuses on advancing innovative cancer therapies through rigorous scientific investigation and collaboration. The center's multidisciplinary team of experts employs cutting-edge methodologies to design and conduct trials that aim to improve patient outcomes and enhance understanding of cancer biology. With a commitment to translating research findings into clinical practice, MSKCC plays a pivotal role in shaping the future of oncology care and ensuring that patients have access to the latest therapeutic advancements.

Locations

Philadelphia, Pennsylvania, United States

New York, New York, United States

Ann Arbor, Michigan, United States

New York, New York, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials